Al MheidI., QuyyumiA.A.Cell therapy in peripheral arterial disease.Angiology.2008; 59: 705–716.
2.
PoredosP., JugB.The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients.Angiology.2007; 58: 309–315.
3.
ParaskevasK.I., PapasT.T., PavlidisP., BessiasN., AndrikopoulosV.The importance of conservative measures in peripheral arterial disease: an update.Angiology.2008; 59: 529–533.
4.
MikroulisD., PapanasN., MaltezosE., BougioukasG.Angiogenic growth factors in the treatment of peripheral arterial disease.Curr Vasc Pharmacol.2007; 5: 195–209.
5.
ParaskevasK.I., MikhailidisD.P.Angiogenesis: a promising treatment option for peripheral arterial disease.Curr Vasc Pharmacol.2008; 6: 78–80.
6.
LinJ.W., SheuW.H., LeeW.J.Circulating hepatocyte growth factor level but not basic fibroblast growth factor level is elevated in angiography-proven symptomatic peripheral artery disease.Angiology.2007; 58: 420–428.
7.
RohovskyS., KearneyM., PieczekA.Elevated levels of basic fibroblast growth factor in patients with limb ischemia.Am Heart J.1996; 132: 1015–1019.
8.
OzawaT., KatoK., SanadaH.Marked decrease of plasma VEGF after implantation of autologous bone marrow mononuclear cells in a patient with critical limb ischemia—a case report.Angiology.2006; 57: 235–239.
9.
HigashiY., KimuraM., HaraK.Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilatation in patients with limb ischemia.Circulation.2004; 109: 1215–1218.
10.
KoshikawaM., Shimodaira, YoshiokaT.Therapeutic angiogenesis by bone marrow implantation of critical hand limb ischemia in patients with peripheral arterial disease: a pilot study.Curr Med Res Opin.2006; 22: 793–798.
11.
Tateishi-YuyamaE., MatsubaraH., and the Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial.Lancet.2002; 360: 427–435.
12.
ParaskevasK.I., StathopoulosV., MikhailidisD.P.Pleiotropic effects of statins: implications for a wide range of diseases.Curr Vasc Pharmacol.2008; 6: 237–239.
13.
TsiaraS., ElisafM., MikhailidisD.P.Early vascular benefits of statin therapy.Curr Med Res Opin.2003; 19: 540–556.
14.
RobinsonJ.G.Simvastatin: present and future perspectives.Expert Opin Pharmacother.2007; 8: 2127–2159.
ParaskevasK.I., HamiltonG., MikhailidisD.P.Statins: an essential component in the management of carotid artery disease.J Vasc Surg.2007; 46: 373–386.
18.
SarafidisP.A., KanakiA.I., LasaridisA.N.Effects of statins on blood pressure: a review of the experimental and clinical evidence.Curr Vasc Pharmacol.2007; 5: 155–161.
19.
HorwichT.B., MacLellanW.R.Atorvastatin and statins in the treatment of heart failure.Expert Opin Pharmacother.2007; 8: 3061–3068.
20.
EfthimiadisA.Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?Angiology.2008; 59(2 suppl): 62S–64S.
21.
FilippatosT.D., MikhailidisD.P.Statins and heart failure.Angiology.2008; 59(2 suppl): 58S–61S.
22.
IsmaN., BaraniJ., MattiassonI., LindbladB., GottsäterA.Lipid-lowering therapy is related to inflammatory markers and 3-year mortality in patients with critical limb ischemia.Angiology.2008; 59: 542–548.
23.
KamishiradoH., InoueT., SakumaM.Effect of statins on restenosis after stent implantation.Angiology.2007; 58: 55–60.
24.
ParaskevasK.I., TzovarasA.A., BrianaD.D., MikhailidisD.P.Emerging indications for statins: a pluripotent family of agents with several potential applications.Curr Pharm Des.2007; 13: 3622–3636.
25.
AmarencoP.Atorvastatin in prevention of stroke and transient ischaemic attack.Expert Opin Pharmacother.2007; 8: 2789–2797.
26.
AthyrosV.G., KakafikaA.I., TziomalosK., PapageorgiouA.A., KaragiannisA.Statins for the prevention of first or recurrent stroke.Curr Vasc Pharmacol.2008; 6: 124–133.
27.
SallustioF., DiomediM., CentonzeD., StanzioneP.Saving the ischemic penumbra: potential role for statins and phosphodiesterase inhibitors.Curr Vasc Pharmacol.2007; 5: 259–265.
28.
DilaverisP., GiannopoulosG., RigaM., SynetosA., StefanadisC.Beneficial effects of statins on endothelial dysfunction and vascular stiffness.Curr Vasc Pharmacol.2007; 5: 227–237.
29.
AshtonJ.C., SmithP.F.Cannabinoids and cardiovascular disease: the outlook for clinical treatments.Curr Vasc Pharmacol.2007; 5: 175–185.
30.
AndrikopoulosG.K., TzeisS.Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.Angiology.2008; 59(2 suppl): 44S–48S.
TziomalosK., AthyrosV.G., KaragiannisA., MikhailidisD.P.Omega-3 Fatty acids: how can they be used in secondary prevention?Curr Atheroscler Rep.2008; 10: 510–517.
Yamaoka-TojoM., TojoT., IzumiT.Beyond cholesterol lowering: pleiotropic effects of bile acid binding resins against cardiovascular disease risk factors in patients with metabolic syndrome.Curr Vasc Pharmacol.2008; 6: 271–281.
35.
YuJ., WeiwerM., LinhardtR.J., DordickJ.S.The role of the methoxyphenol apocynin, a vascular NADPH oxidase inhibitor, as a chemopreventative agent in the potential treatment of cardiovascular diseases.Curr Vasc Pharmacol.2008; 6: 204–217.
36.
TomitaN., MorishitaR.Antisense oligonucleotides as a powerful molecular strategy for gene therapy in cardiovascular diseases.Curr Pharm Des.2004; 10: 797–803.
37.
AthyrosV.G., KakafikaA.I., TziomalosK., KaragiannisA., MikhailidisD.P.Antisense technology for the prevention or treatment of cardiovascular diseases: the next blockbuster?Expert Opin Investig Drugs.2008; 17: 969–972.
